公开(公告)号：US20230330251A1

公开(公告)日：2023-10-19

申请号：US18025349

申请日：2021-09-16

申请人： AGENSYS, INC. ,  SEAGEN INC.

发明人： Elaina Marie GARTNER

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K47/6849 ,  A61P35/00 ,  C07K16/2803 ,  A61K47/6817 ,  A61K47/6889 ,  A61K2039/505

摘要： Provided herein are methods for the treatment of cancers with antibody drug conjugates (ADC) that bind to 191P4D12 proteins.

公开(公告)号：US10787517B2

公开(公告)日：2020-09-29

申请号：US15572739

申请日：2016-05-18

申请人： AGENSYS, INC.

发明人： Karen Jane Meyrick Morrison

IPC分类号： G01N31/00 ,  G01N33/53 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574 ,  A61K39/00

摘要： Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.

公开(公告)号：US20200231670A1

公开(公告)日：2020-07-23

申请号：US16619439

申请日：2018-06-04

申请人： AGENSYS, INC.

发明人： Karen Jane Meyrick MORRISON ,  Fernando DONATE ,  Peng YANG

IPC分类号： C07K16/28 ,  G01N33/574

摘要： Provided herein are compositions, methods and uses involving antibodies that specifically bind to Nectin-4. Also provided herein are methods for assessing Nectin-4 expression in a sample or a patient and methods for assessing responsiveness of a cancer patient to an anti-cancer therapeutic agent.

公开(公告)号：USRE47103E1

公开(公告)日：2018-10-30

申请号：US15448507

申请日：2017-03-02

申请人： Agensys, Inc. ,  Seattle Genetics, Inc.

发明人： Robert Kendall Morrison ,  Zili An ,  Karen Jane Meyrick Morrison ,  Josh Snyder ,  Xiao-Chi Jia

IPC分类号： A61K39/395 ,  C07K16/30 ,  C07K16/18 ,  A61K45/06 ,  A61K47/68 ,  A61K39/00

摘要： Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

公开(公告)号：US09925273B2

公开(公告)日：2018-03-27

申请号：US14447209

申请日：2014-07-30

申请人： AGENSYS, INC.

发明人： Daniel Sousa Pereira ,  Faisal Hayat Malik ,  Josh Snyder ,  Leslie Renee Butterworth ,  Ssucheng Jeff Hsu ,  Peng Yang ,  Claudia Isabel Guevara

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61K45/06

CPC分类号： A61K47/6851 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6849

摘要： Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.

公开(公告)号：US20180037657A1

公开(公告)日：2018-02-08

申请号：US15556587

申请日：2016-03-09

申请人： AGENSYS, INC.

发明人： Nandini RUDRA-GANGULY ,  Christine LOWE ,  Faisal Hayat MALIK ,  Sung Ju MOON ,  Josh SNYDER ,  Hector AVINA ,  Cyrus VIRATA ,  Linnette CAPO ,  Gao LIU

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K47/68

摘要： Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

公开(公告)号：US09617346B2

公开(公告)日：2017-04-11

申请号：US14604658

申请日：2015-01-23

申请人： AGENSYS, INC.

发明人： Aya Jakobovits ,  Soudabeh Etessami ,  Pia M. Challita-Eid ,  Juan J. Perez-Villar ,  Karen J. Morrison ,  Xiao-Chi Jia ,  Mary Faris ,  Jean Gudas ,  Arthur B. Raitano

IPC分类号： C07H21/04 ,  C07K16/40 ,  A61K39/395 ,  A61K45/06 ,  A61K47/48 ,  A61K51/10 ,  C07K16/30 ,  G01N33/68 ,  A61K39/00

CPC分类号： C07K16/40 ,  A61K39/39533 ,  A61K45/06 ,  A61K47/48607 ,  A61K47/6861 ,  A61K51/106 ,  A61K51/1075 ,  A61K2039/505 ,  C07H21/04 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/565 ,  G01N33/6887 ,  A61K2300/00

摘要： Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

公开(公告)号：US08853364B2

公开(公告)日：2014-10-07

申请号：US12561832

申请日：2009-09-17

申请人： Wangmao Ge ,  Pia M. Challita-Eid ,  Arthur B. Raitano ,  Aya Jakobovits

发明人： Wangmao Ge ,  Pia M. Challita-Eid ,  Arthur B. Raitano ,  Aya Jakobovits

IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/00 ,  A61K51/10 ,  C07K16/30 ,  C07K14/705 ,  G01N33/574 ,  C07K14/47 ,  G01N33/566

CPC分类号： C07K14/4748 ,  A61K39/0011 ,  A61K51/1051 ,  A61K51/1054 ,  A61K51/1057 ,  A61K51/106 ,  A61K51/1072 ,  A61K2039/53 ,  C07K14/705 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/73 ,  G01N33/566 ,  G01N33/57415 ,  Y02A50/466

摘要： PSCA and its encoded protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.

摘要翻译： 描述了PSCA及其编码的蛋白及其变体，其中PSCA在正常成人组织中显示组织特异性表达，并且在表I中列出的癌症中异常表达。因此，PSCA提供诊断，预后，预防和/或治疗靶标 为癌症。 PSCA基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与PSCA反应的抗体或T细胞可用于主动或被动免疫。

公开(公告)号：US08637642B2

公开(公告)日：2014-01-28

申请号：US13249111

申请日：2011-09-29

申请人： Daulet Satpayev ,  Robert Kendall Morrison ,  Karen Jane Meyrick Morrison ,  Jean Gudas ,  Aya Jakobovits ,  Michael Torgov ,  Zili An

发明人： Daulet Satpayev ,  Robert Kendall Morrison ,  Karen Jane Meyrick Morrison ,  Jean Gudas ,  Aya Jakobovits ,  Michael Torgov ,  Zili An

IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/00

CPC分类号： A61K47/6851 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6861 ,  A61K47/6889 ,  A61K2039/505 ,  A61N5/1001 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

摘要： Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

摘要翻译： 本文描述了结合191P4D12蛋白及其变体的抗体药物偶联物（ADC）。 191P4D12在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，本发明的ADC提供了用于治疗癌症的治疗组合物。

公开(公告)号：US08497351B2

公开(公告)日：2013-07-30

申请号：US13043221

申请日：2011-03-08

申请人： Pia M. Challita-Eid ,  Arthur B. Raitano ,  Mary Faris ,  Rene S. Hubert ,  Karen Jane Meyrick Morrison ,  Robert Kendall Morrison ,  Wangmao Ge ,  Aya Jakobovits

发明人： Pia M. Challita-Eid ,  Arthur B. Raitano ,  Mary Faris ,  Rene S. Hubert ,  Karen Jane Meyrick Morrison ,  Robert Kendall Morrison ,  Wangmao Ge ,  Aya Jakobovits

IPC分类号： C07K5/00

CPC分类号： C07K14/4748 ,  A61K39/00 ,  Y02A50/466 ,  Y10T436/143333

摘要： A novel gene (designated 162P1E6) and its encoded protein, and variants thereof, are described wherein 162P1E6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 162P1E6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 162P1E6 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 162P1E6 can be used in active or passive immunization.

摘要翻译： 描述了一种新型基因（命名为162P1E6）及其编码的蛋白质及其变体，其中162P1E6在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，162P1E6提供诊断，预后， 癌症的预防和/或治疗靶标。 162P1E6基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与162P1E6反应的抗体或T细胞可用于主动或被动免疫。